Skip to content
10-Q

Quarterly Report

Amylyx Pharmaceuticals, Inc. AMLX

0001193125-25-268059

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 27, 2025 109.82M sh
Shares Diluted Q3 2025 · Sep 30, 2025 93.33M sh
Shares Diluted Q3 2025 · Sep 30, 2025 89.42M sh
Shares Diluted Q3 2025 · Sep 30, 2024 68.09M sh
Shares Diluted Q3 2025 · Sep 30, 2024 67.99M sh
Capex Q3 2025 · Sep 30, 2025 $52K
Capex Q3 2025 · Sep 30, 2024 $137K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$95.44M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$108.64M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $225.18M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $77.39M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $71.84M
Stockholders Equity Q3 2025 · Sep 30, 2025 $332M
Stockholders Equity Q3 2025 · Jun 30, 2025 $167.88M
Stockholders Equity Q3 2025 · Mar 31, 2025 $201.42M
Stockholders Equity Q3 2025 · Dec 31, 2024 $164.77M
Stockholders Equity Q3 2025 · Sep 30, 2024 $196.2M
Stockholders Equity Q3 2025 · Jun 30, 2024 $261.31M
Stockholders Equity Q3 2025 · Mar 31, 2024 $324.44M
Stockholders Equity Q3 2025 · Dec 31, 2023 $433.43M
Current Liabilities Q3 2025 · Sep 30, 2025 $25.79M
Current Liabilities Q3 2025 · Dec 31, 2024 $28.41M
Total Liabilities Q3 2025 · Sep 30, 2025 $30.75M
Total Liabilities Q3 2025 · Dec 31, 2024 $28.87M
Current Assets Q3 2025 · Sep 30, 2025 $353.38M
Current Assets Q3 2025 · Dec 31, 2024 $189.43M
Total Assets Q3 2025 · Sep 30, 2025 $362.74M
Total Assets Q3 2025 · Dec 31, 2024 $193.63M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.37
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.25
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.07
Eps Diluted Q3 2025 · Sep 30, 2024 −$3.89
Eps Basic Q3 2025 · Sep 30, 2025 −$0.37
Eps Basic Q3 2025 · Sep 30, 2025 −$1.25
Eps Basic Q3 2025 · Sep 30, 2024 −$1.07
Eps Basic Q3 2025 · Sep 30, 2024 −$3.89
Sga Expense Q3 2025 · Sep 30, 2025 $16.17M
Sga Expense Q3 2025 · Sep 30, 2025 $47.5M
Sga Expense Q3 2025 · Sep 30, 2024 $17.83M
Sga Expense Q3 2025 · Sep 30, 2024 $97.23M
Rd Expense Q3 2025 · Sep 30, 2025 $19.86M
Rd Expense Q3 2025 · Sep 30, 2025 $69.19M
Rd Expense Q3 2025 · Sep 30, 2024 $21.24M
Rd Expense Q3 2025 · Sep 30, 2024 $81.19M
Net Income Q3 2025 · Sep 30, 2025 −$34.39M
Net Income Q3 2025 · Sep 30, 2025 −$111.74M
Net Income Q3 2025 · Jun 30, 2025 −$41.44M
Net Income Q3 2025 · Mar 31, 2025 −$35.91M
Net Income Q3 2025 · Sep 30, 2024 −$72.7M
Net Income Q3 2025 · Sep 30, 2024 −$264.2M
Net Income Q3 2025 · Jun 30, 2024 −$72.7M
Net Income Q3 2025 · Mar 31, 2024 −$118.79M
Operating Income Q3 2025 · Sep 30, 2025 −$36.03M
Operating Income Q3 2025 · Sep 30, 2025 −$116.69M
Operating Income Q3 2025 · Sep 30, 2024 −$75.66M
Operating Income Q3 2025 · Sep 30, 2024 −$274.08M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $0
Cost Of Revenue Q3 2025 · Sep 30, 2025 $0
Cost Of Revenue Q3 2025 · Sep 30, 2024 $0
Cost Of Revenue Q3 2025 · Sep 30, 2024 $5.95M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2024 $416K
Revenue Q3 2025 · Sep 30, 2024 $88.04M